A Phase 3 interventional study of Axitinib (AG-013736) and Sorafenib in Kidney Neoplasms, sponsored by Pfizer. Completed at 294 sites in 22 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-01-09.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing axitinib in Kidney Neoplasms — 3 open to participants now, 3 under way, 1 of them phase 3. Axitinib · Kidney Neoplasms.
Among the 12 studies testing axitinib in Kidney Neoplasms, this one is the 3rd largest by enrollment, is the only one that started in 2008, is one of 4 in phase 3, and was the 2nd registered.
969 studies on the registry are indexed under Kidney Neoplasms; 210 are open to participants now.
Browse Kidney Neoplasms studies →3 of the 12 studies testing axitinib in Kidney Neoplasms are open now, in 5 countries. Recruiting first, the newest first:
Stephanie Berg · Sites in United States
Ages 18+
Gustave Roussy, Cancer Campus, Grand Paris · Sites in Austria, Czechia, France and 1 more country
Ages 18+
University of Colorado, Denver · Sites in United States
Ages 18+
By country, each count listing its studies:
Axitinib: first FDA approval 2012 (INLYTA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 173 Kidney Neoplasms studies recruiting now, 133 (77%) set no upper age limit and 15 (9%) stop at 75 or younger; 20 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 8 · Phase 3 4
First in 2006; this study’s year is marked. 1 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 723 is above the median of 46 across 668 interventional studies indexed under Kidney Neoplasms.
Median enrollment 54 across the 12 interventional studies. Of the 9 that completed or were terminated, 9 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 12 have an industry lead sponsor. The 8 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
21 studies in Kidney Neoplasms by Pfizer: 1 open now, 1 under way, none of them phase 3. Of 19 finished, 15 (79%) have results posted.
Among the 21 studies in Kidney Neoplasms by Pfizer, this one is the 3rd largest by enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2008, is one of 6 in phase 3, and was the 8th registered.
Pfizer’s Kidney Neoplasms studies by the year they started, since 2003.
1 of the studies testing axitinib in Kidney Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07123090Stephanie BergA Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma | 2027-10-01 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing axitinib in Kidney Neoplasms, from their registry updates:
Among Pfizer’s 21 in Kidney Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study is designed to demonstrate that axitinib (AG-013736) is superior to sorafenib in delaying tumor progression in patients with metastatic renal cell cancer after failure of one first line regimen.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Axitinib (AG-013736)
Drug: Sorafenib
axitinib will be given at a starting dose of 5 mg twice daily \[BID\] with continuous dosing
sorafenib will be given at a dose of 400 mg twice daily \[BID\] with continuous dosing
Progression-Free Survival (PFS)
PFS was defined as the time in months from start of study treatment to the first documentation of objective tumor progression of disease (PD) or to death due to any cause, whichever occurs first. PD was assessed by response evaluation criteria in solid tumors (RECIST) version 1.0. PD: \>=20 percent (%) increase in the sum of the longest dimensions (LD) of the target lesions taking as a reference the smallest sum of the LD recorded since the start of treatment or unequivocal progression in non-target lesions or the appearance of 1 or more new lesions. Occurrence of a pleural effusion or ascites was also considered PD if demonstrated by cytological investigation and it was not previously documented. New bone lesions not previously documented were considered PD if confirmed by computed tomography/magnetic resonance imaging or X-ray.
Time frame: From initiation of treatment up to follow-up period (up to 3 years)
Overall Survival (OS)
OS was defined as the duration from start of study treatment to date of death due to any cause. OS was calculated as (months) = (date of death minus the date of first dose of study medication plus 1) divided by 30.4. For participants who were alive, overall survival was censored on last date the participants were known to be alive.
Time frame: From initiation of treatment up to follow-up period (up to 3 years)
Objective Response Rate (ORR)
ORR = percentage of participants with confirmed complete response (CR) or confirmed partial response (PR) according to RECIST version 1.0 recorded from first dose of study treatment until PD or death due to any cause. CR: disappearance of all target, non target lesions and no appearance of new lesions, documented on 2 occasions separated by at least 4 weeks. PR: at least 30 % decrease in sum of LD of target lesions taking as reference baseline sum of LD, without progression of non target lesions, no appearance of new lesions. PD: \>=20% increase in sum of LD of the target lesions taking as a reference smallest sum of LD recorded since the start of treatment or unequivocal progression in non-target lesions or appearance of 1 or more new lesions. Occurrence of pleural effusion or ascites if demonstrated by cytological investigation, not previously documented. New bone lesions not previously documented if confirmed by computed tomography/magnetic resonance imaging or X-ray.
Time frame: From initiation of treatment up to follow-up period (up to 3 years)
Duration of Response (DR)
DR: time from first documentation of objective tumor response (CR or PR), that was subsequently confirmed, to the first documentation of PD or to death due to any cause, whichever occurred first as per RECIST version 1.0, a) CR: disappearance of all target, non target lesions and no appearance of new lesions, documented on 2 occasions separated by at least 4 weeks, b) PR: at least 30 % decrease in sum of LD of target lesions taking as reference baseline sum of LD, without progression of non target lesions, no appearance of new lesions, c) PD: \>=20% increase in sum of LD of the target lesions taking as a reference smallest sum of LD recorded since the start of treatment or unequivocal progression in non-target lesions or appearance of 1 or more new lesions. Occurrence of pleural effusion or ascites if demonstrated by cytological investigation, not previously documented. New bone lesions not previously documented if confirmed by computed tomography/magnetic resonance imaging or X-ray.
Time frame: From initiation of treatment up to follow-up period (up to 3 years)
Percentage of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life- threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included both serious and non-serious AEs.
Time frame: From initiation of treatment up to follow-up period (up to 3 years)
Percentage of Participants With Adverse Events (AEs) by Severity
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Severity of the AEs was graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. Grade 1= mild; Grade 2= moderate; Grade 3= severe; Grade 4= life-threatening or disabling; Grade 5= death related to AE.
Time frame: From initiation of treatment up to follow-up period (up to 3 years)
Percentage of Participants With Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life -threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both serious and non -serious AEs.
Time frame: From initiation of treatment up to follow-up period (up to 3 years)
Number of Participants With Clinically Significant Laboratory Abnormalities: Hematology
Hematology laboratory test included hemoglobin, platelet count, white blood cells count, neutrophils and lymphocytes. Abnormalities were assessed by CTCAE Grade Version 2 for severity: Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling.
Time frame: From initiation of treatment up to follow-up period (up to 3 years)
Number of Participants With Clinically Significant Laboratory Abnormalities: Biochemistry
Biochemistry laboratory test included parameters: alanine aminotransferase, alkaline phosphatase, amylase, aspartate aminotransferase, bicarbonate, bilirubin, creatinine, hypercalcemia, hyperglycemia, hyperkalemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hyponatremia, hypophosphatemia and lipase. Abnormalities were assessed by CTCAE Grade Version 2 for severity: Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling.
Time frame: From initiation of treatment up to follow-up period (up to 3 years)
Number of Participants With Clinically Significant Laboratory Abnormalities: Urinalysis
Urinalysis included urine blood/ hemoglobin, glucose and protein. Abnormalities were assessed by CTCAE Grade Version 2 for severity: Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling.
Time frame: From initiation of treatment up to follow-up period (up to 3 years)
Functional Assessment of Cancer Therapy Kidney Symptom Index-15 (FKSI-15) Score
FKSI was used to assess quality of life (QoL) for those diagnosed with renal cell cancer and consisted of 15 items (lack of energy, side effects, pain, losing weight, bone pain, fatigue, enjoying life, short of breath, worsened condition, appetite, coughing, bothered by fevers, ability to work, hematuria and sleep). Each of the 15 items was answered on a 5-point Likert-type scale ranging from 0 to 4 (0= not at all, 1= a little bit, 2= somewhat, 3= quite a bit, 4= very much). Total FKSI score = sum of the 15 item scores; total range: 0 - 60; 0 (no symptoms) to 60 (very much); higher scores indicate greater presence of symptoms.
Time frame: Baseline (Predose on Cycle 1 Day 1) , Day 1 of each cycle until Cycle 21, End of treatment (Day 670) and Follow-up visit (Day 698)
Functional Assessment of Cancer Therapy Kidney Symptom Index-Disease Related Symptoms (FKSI-DRS) Score
FKSI-DRS was used to assess quality of life for those diagnosed with renal cell cancer and consisted of 9 items (lack of energy, pain, losing weight, bone pain, fatigue, short of breath, coughing, bothered by fevers, and hematuria). Each of the 9 items was answered on a 5-point Likert-type scale ranging from 0 to 4 (0= not at all, 1= a little bit, 2= somewhat, 3= quite a bit, 4= very much). Total FKSI-DRS score = sum of the 9 item scores; total range: 0 - 36; 0 (no symptoms) to 36 (very much); higher scores indicate greater presence of symptoms.
Time frame: Baseline (Predose on Cycle 1 Day 1) , Day 1 of each cycle until Cycle 21, End of treatment (Day 670) and Follow-up visit (Day 698)
Euro Quality of Life Questionnaire- 5 Dimension (EQ-5D): Health State Profile Utility Score
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility or index score. Health state profile component assesses level of health for 5 domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each domain was rated on a 3-point response scale (1= no problems, 2= some/moderate problems and 3= extreme problems). Scoring formula developed by EuroQol Group assigned a utility value for each domain in the profile. Score were transformed and resulted in a total score range of 0 to 1, with higher scores indicating better health.
Time frame: Baseline (Predose on Cycle 1 Day 1) , Day 1 of each cycle until Cycle 21, End of treatment (Day 670) and Follow-up visit (Day 698)
Euro Quality of Life Questionnaire- 5 Dimension (EQ-5D): Visual Analog Scale (VAS)
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. VAS component: participants rated their current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health.
Time frame: Baseline (Predose on Cycle 1 Day 1) , Day 1 of each cycle until Cycle 21, End of treatment (Day 670) and Follow-up visit (Day 698)
| Milestone | Axitinib 5 mg | Sorafenib 400 mg |
|---|---|---|
| Started | 361 | 362 |
| Treated | 359 | 355 |
| Completed | 0 | 0 |
| Not completed | 361 | 362 |
| Withdrew: Adverse event | 0 | 6 |
| Withdrew: Death | 280 | 269 |
| Withdrew: Lost to follow-up | 15 | 13 |
| Withdrew: Objective progression or relapse | 3 | 8 |
| Withdrew: Sponsor's decision | 1 | 2 |
| Withdrew: Withdrawal by subject | 4 | 4 |
| Withdrew: Randomized but not treated | 2 | 7 |
| Withdrew: Other | 56 | 53 |
PFS was defined as the time in months from start of study treatment to the first documentation of objective tumor progression of disease (PD) or to death due to any cause, whichever occurs first. PD was assessed by response evaluation criteria in solid tumors (RECIST) version 1.0. PD: \>=20 percent (%) increase in the sum of the longest dimensions (LD) of the target lesions taking as a reference the smallest sum of the LD recorded since the start of treatment or unequivocal progression in non-target lesions or the appearance of 1 or more new lesions. Occurrence of a pleural effusion or ascites was also considered PD if demonstrated by cytological investigation and it was not previously documented. New bone lesions not previously documented were considered PD if confirmed by computed tomography/magnetic resonance imaging or X-ray.
| Months | Axitinib 5 mg | Sorafenib 400 mg |
|---|---|---|
| Progression-Free Survival (PFS) | 6.7 (6.3 to 8.6) | 4.7 (4.6 to 5.6) |
OS was defined as the duration from start of study treatment to date of death due to any cause. OS was calculated as (months) = (date of death minus the date of first dose of study medication plus 1) divided by 30.4. For participants who were alive, overall survival was censored on last date the participants were known to be alive.
| Months | Axitinib 5 mg | Sorafenib 400 mg |
|---|---|---|
| Overall Survival (OS) | 20.1 (16.7 to 23.4) | 19.2 (17.5 to 22.3) |
ORR = percentage of participants with confirmed complete response (CR) or confirmed partial response (PR) according to RECIST version 1.0 recorded from first dose of study treatment until PD or death due to any cause. CR: disappearance of all target, non target lesions and no appearance of new lesions, documented on 2 occasions separated by at least 4 weeks. PR: at least 30 % decrease in sum of LD of target lesions taking as reference baseline sum of LD, without progression of non target lesions, no appearance of new lesions. PD: \>=20% increase in sum of LD of the target lesions taking as a reference smallest sum of LD recorded since the start of treatment or unequivocal progression in non-target lesions or appearance of 1 or more new lesions. Occurrence of pleural effusion or ascites if demonstrated by cytological investigation, not previously documented. New bone lesions not previously documented if confirmed by computed tomography/magnetic resonance imaging or X-ray.
| Percentage of participants | Axitinib 5 mg | Sorafenib 400 mg |
|---|---|---|
| Objective Response Rate (ORR) | 19.4 (15.4 to 23.9) | 9.4 (6.6 to 12.9) |
DR: time from first documentation of objective tumor response (CR or PR), that was subsequently confirmed, to the first documentation of PD or to death due to any cause, whichever occurred first as per RECIST version 1.0, a) CR: disappearance of all target, non target lesions and no appearance of new lesions, documented on 2 occasions separated by at least 4 weeks, b) PR: at least 30 % decrease in sum of LD of target lesions taking as reference baseline sum of LD, without progression of non target lesions, no appearance of new lesions, c) PD: \>=20% increase in sum of LD of the target lesions taking as a reference smallest sum of LD recorded since the start of treatment or unequivocal progression in non-target lesions or appearance of 1 or more new lesions. Occurrence of pleural effusion or ascites if demonstrated by cytological investigation, not previously documented. New bone lesions not previously documented if confirmed by computed tomography/magnetic resonance imaging or X-ray.
| Months | Axitinib 5 mg | Sorafenib 400 mg |
|---|---|---|
| Duration of Response (DR) | 11.0 (7.4 to NA) | 10.6 (8.8 to 11.5) |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life- threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included both serious and non-serious AEs.
| Percentage of participants | Axitinib 5 mg | Sorafenib 400 mg |
|---|---|---|
| AEs | 96.1 | 98.0 |
| SAEs | 40.7 | 35.8 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Severity of the AEs was graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. Grade 1= mild; Grade 2= moderate; Grade 3= severe; Grade 4= life-threatening or disabling; Grade 5= death related to AE.
| Percentage of participants | Axitinib 5 mg | Sorafenib 400 mg |
|---|---|---|
| Grade 1 | 3.9 | 3.1 |
| Grade 2 | 20.1 | 21.7 |
| Grade 3 | 47.6 | 52.4 |
| Grade 4 | 10.6 | 11.5 |
| Grade 5 | 13.9 | 9.3 |
An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life -threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both serious and non -serious AEs.
| Percentage of participants | Axitinib 5 mg | Sorafenib 400 mg |
|---|---|---|
| AEs | 92.2 | 95.2 |
| SAEs | 15.3 | 13.8 |
Hematology laboratory test included hemoglobin, platelet count, white blood cells count, neutrophils and lymphocytes. Abnormalities were assessed by CTCAE Grade Version 2 for severity: Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling.
| Participants | Axitinib 5 mg | Sorafenib 400 mg |
|---|---|---|
| Hemoglobin: Grade 1 (n =320, 316) | 93 | 112 |
| Hemoglobin: Grade 2 (n =320, 316) | 19 | 41 |
| Hemoglobin: Grade 3 (n =320, 316) | 1 | 11 |
| Hemoglobin: Grade 4 (n =320, 316) | 0 | 1 |
| Lymphocytes: Grade 1 (n =317, 309) | 7 | 7 |
| Lymphocytes: Grade 2 (n =317, 309) | 89 | 93 |
| Lymphocytes: Grade 3 (n =317, 309) | 10 | 11 |
| Lymphocytes: Grade 4 (n =317, 309) | 0 | 0 |
| Neutrophils: Grade 1 (n =316, 308) | 13 | 20 |
| Neutrophils: Grade 2 (n =316, 308) | 4 | 4 |
| Neutrophils: Grade 3 (n =316, 308) | 2 | 2 |
| Neutrophils: Grade 4 (n =316, 308) | 0 | 0 |
| Platelets: Grade 1 (n =312, 310) | 47 | 41 |
| Platelets: Grade 2 (n =312, 310) | 0 | 3 |
| Platelets: Grade 3 (n =312, 310) | 1 | 0 |
| Platelets: Grade 4 (n =312, 310) | 0 | 0 |
| White Blood Cells: Grade 1 (n =320, 315) | 32 | 36 |
| White Blood Cells: Grade 2 (n =320, 315) | 4 | 12 |
| White Blood Cells: Grade 3 (n =320, 315) | 0 | 1 |
| White Blood Cells: Grade 4 (n =320, 315) | 0 | 0 |
Biochemistry laboratory test included parameters: alanine aminotransferase, alkaline phosphatase, amylase, aspartate aminotransferase, bicarbonate, bilirubin, creatinine, hypercalcemia, hyperglycemia, hyperkalemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hyponatremia, hypophosphatemia and lipase. Abnormalities were assessed by CTCAE Grade Version 2 for severity: Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling.
| Participants | Axitinib 5 mg | Sorafenib 400 mg |
|---|---|---|
| Alanine aminotransferase: Grade 1 (n =331, 313) | 65 | 57 |
| Alanine aminotransferase: Grade 2 (n =331, 313) | 8 | 6 |
| Alanine aminotransferase: Grade 3 (n =331, 313) | 1 | 2 |
| Alanine aminotransferase: Grade 4 (n =331, 313) | 0 | 3 |
| Alkaline phosphatase: Grade 1 (n =336, 319) | 88 | 92 |
| Alkaline phosphatase: Grade 2 (n =336, 319) | 8 | 15 |
| Alkaline phosphatase: Grade 3 (n =336, 319) | 4 | 3 |
| Alkaline phosphatase: Grade 4 (n =336, 319) | 0 | 0 |
| Amylase: Grade 1 (n =338, 319) | 64 | 76 |
| Amylase: Grade 2 (n =338, 319) | 12 | 21 |
| Amylase: Grade 3 (n =338, 319) | 7 | 6 |
| Amylase: Grade 4 (n =338, 319) | 0 | 1 |
| Aspartate aminotransferase: Grade 1 (n =331, 311) | 59 | 67 |
| Aspartate aminotransferase: Grade 2 (n =331, 311) | 5 | 7 |
| Aspartate aminotransferase: Grade 3 (n =331, 311) | 1 | 4 |
| Aspartate aminotransferase: Grade 4 (n =331, 311) | 0 | 0 |
| Bicarbonate: Grade 1 (n =314, 291) | 127 | 115 |
| Bicarbonate: Grade 2 (n =314, 291) | 11 | 10 |
| Bicarbonate: Grade 3 (n =314, 291) | 0 | 0 |
| Bicarbonate: Grade 4 (n =314, 291) | 1 | 0 |
| Bilirubin: Grade 1 (n =336, 318) | 16 | 12 |
| Bilirubin: Grade 2 (n =336, 318) | 8 | 2 |
| Bilirubin: Grade 3 (n =336, 318) | 1 | 1 |
| Bilirubin: Grade 4 (n =336, 318) | 0 | 0 |
| Creatinine: Grade 1 (n =336, 318) | 155 | 121 |
| Creatinine: Grade 2 (n =336, 318) | 30 | 9 |
| Creatinine: Grade 3 (n =336, 318) | 0 | 1 |
| Creatinine: Grade 4 (n =336, 318) | 0 | 0 |
| Hypercalcemia: Grade 1 (n =336, 319) | 92 | 22 |
| Hypercalcemia: Grade 2 (n =336, 319) | 8 | 1 |
| Hypercalcemia: Grade 3 (n =336, 319) | 1 | 0 |
| Hypercalcemia: Grade 4 (n =336, 319) | 0 | 0 |
| Hyperglycemia: Grade 1 (n =336, 319) | 41 | 28 |
| Hyperglycemia: Grade 2 (n =336, 319) | 45 | 37 |
| Hyperglycemia: Grade 3 (n =336, 319) | 7 | 7 |
| Hyperglycemia: Grade 4 (n =336, 319) | 0 | 0 |
| Hyperkalemia: Grade 1 (n =333, 314) | 0 | 0 |
| Hyperkalemia: Grade 2 (n =333, 314) | 42 | 22 |
| Hyperkalemia: Grade 3 (n =333, 314) | 9 | 8 |
| Hyperkalemia: Grade 4 (n =333, 314) | 0 | 0 |
| Hypernatremia: Grade 1 (n =338, 319) | 34 | 23 |
| Hypernatremia: Grade 2 (n =338, 319) | 19 | 14 |
| Hypernatremia: Grade 3 (n =338, 319) | 3 | 1 |
| Hypernatremia: Grade 4 (n =338, 319) | 0 | 2 |
| Hypoalbuminemia: Grade 1 (n =337, 319) | 37 | 25 |
| Hypoalbuminemia: Grade 2 (n =337, 319) | 11 | 31 |
| Hypoalbuminemia: Grade 3 (n =337, 319) | 1 | 2 |
| Hypoalbuminemia: Grade 4 (n =337, 319) | 0 | 0 |
| Hypocalcemia: Grade 1 (n =336, 319) | 25 | 67 |
| Hypocalcemia: Grade 2 (n =336, 319) | 4 | 18 |
| Hypocalcemia: Grade 3 (n =336, 319) | 2 | 2 |
| Hypocalcemia: Grade 4 (n =336, 319) | 1 | 2 |
| Hypoglycemia: Grade 1 (n =336, 319) | 23 | 9 |
| Hypoglycemia: Grade 2 (n =336, 319) | 12 | 16 |
| Hypoglycemia: Grade 3 (n =336, 319) | 1 | 1 |
| Hypoglycemia: Grade 4 (n =336, 319) | 0 | 0 |
| Hypokalemia: Grade 1 (n =333, 314) | 22 | 21 |
| Hypokalemia: Grade 2 (n =333, 314) | 0 | 0 |
| Hypokalemia: Grade 3 (n =333, 314) | 0 | 5 |
| Hypokalemia: Grade 4 (n =333, 314) | 0 | 0 |
| Hyponatremia: Grade 1 (n =338, 319) | 33 | 27 |
| Hyponatremia: Grade 2 (n =338, 319) | 0 | 0 |
| Hyponatremia: Grade 3 (n =338, 319) | 11 | 6 |
| Hyponatremia: Grade 4 (n =338, 319) | 1 | 1 |
| Hypophosphatemia: Grade 1 (n =336, 318) | 4 | 8 |
| Hypophosphatemia: Grade 2 (n =336, 318) | 33 | 99 |
| Hypophosphatemia: Grade 3 (n =336, 318) | 6 | 51 |
| Hypophosphatemia: Grade 4 (n =336, 318) | 0 | 0 |
| Lipase: Grade 1 (n =338, 319) | 53 | 76 |
| Lipase: Grade 2 (n =338, 319) | 22 | 25 |
| Lipase: Grade 3 (n =338, 319) | 14 | 40 |
| Lipase: Grade 4 (n =338, 319) | 2 | 7 |
Urinalysis included urine blood/ hemoglobin, glucose and protein. Abnormalities were assessed by CTCAE Grade Version 2 for severity: Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling.
| Participants | Axitinib 5 mg | Sorafenib 400 mg |
|---|---|---|
| Urine blood/ hemoglobin: Grade 1 (n =304, 272) | 45 | 35 |
| Urine blood/ hemoglobin: Grade 2 (n =304, 272) | 1 | 0 |
| Urine blood/ hemoglobin: Grade 3 (n =304, 272) | 0 | 0 |
| Urine blood/ hemoglobin: Grade 4 (n =304, 272) | 0 | 0 |
| Urine glucose: Grade 1 (n =322, 286) | 12 | 13 |
| Urine glucose: Grade 2 (n =322, 286) | 0 | 3 |
| Urine glucose: Grade 3 (n =322, 286) | 0 | 0 |
| Urine glucose: Grade 4 (n =322, 286) | 1 | 1 |
| Urine protein: Grade 1 (n =326, 289) | 105 | 91 |
| Urine protein: Grade 2 (n =326, 289) | 31 | 27 |
| Urine protein: Grade 3 (n =326, 289) | 27 | 21 |
| Urine protein: Grade 4 (n =326, 289) | 9 | 7 |
FKSI was used to assess quality of life (QoL) for those diagnosed with renal cell cancer and consisted of 15 items (lack of energy, side effects, pain, losing weight, bone pain, fatigue, enjoying life, short of breath, worsened condition, appetite, coughing, bothered by fevers, ability to work, hematuria and sleep). Each of the 15 items was answered on a 5-point Likert-type scale ranging from 0 to 4 (0= not at all, 1= a little bit, 2= somewhat, 3= quite a bit, 4= very much). Total FKSI score = sum of the 15 item scores; total range: 0 - 60; 0 (no symptoms) to 60 (very much); higher scores indicate greater presence of symptoms.
| Units on a scale | Axitinib 5 mg | Sorafenib 400 mg |
|---|---|---|
| Baseline (n =346, 342) | 43.199 ± 8.416 | 43.339 ± 8.162 |
| Cycle 2/Day1 (n =319, 296) | 42.351 ± 8.305 | 41.668 ± 7.696 |
| Cycle 3/Day1 (n =279, 246) | 42.590 ± 7.729 | 42.424 ± 7.888 |
| Cycle 4/Day1 (n =257, 221) | 42.791 ± 8.180 | 43.424 ± 7.345 |
| Cycle 5/Day1 (n =238, 203) | 42.968 ± 8.152 | 42.907 ± 7.255 |
| Cycle 6/Day1 (n =213, 179) | 42.949 ± 7.842 | 43.057 ± 7.724 |
| Cycle 7/Day1 (n =206, 158) | 42.747 ± 7.621 | 43.578 ± 7.621 |
| Cycle 8/Day1 (n =177, 136) | 43.580 ± 7.578 | 44.074 ± 7.757 |
| Cycle 9/Day1 (n =163, 118) | 43.191 ± 8.300 | 44.518 ± 6.511 |
| Cycle 10/Day1 (n =146, 96) | 43.312 ± 8.564 | 44.771 ± 7.155 |
| Cycle 11/Day1 (n =122, 85) | 44.119 ± 8.306 | 44.438 ± 7.388 |
| Cycle 12/Day1 (n =110, 70) | 44.517 ± 8.212 | 44.357 ± 7.247 |
| Cycle 13/Day1 (n =92, 58) | 44.492 ± 7.972 | 45.261 ± 7.840 |
| Cycle 14/Day1 (n =81, 54) | 44.485 ± 8.204 | 44.898 ± 7.495 |
| Cycle 15/Day1 (n =61, 38) | 45.291 ± 7.095 | 45.053 ± 6.682 |
| Cycle 16/Day1 (n =52, 34) | 45.217 ± 7.656 | 44.445 ± 7.160 |
| Cycle 17/Day1 (n =47, 28) | 45.242 ± 7.344 | 44.438 ± 7.683 |
| Cycle 18/Day1 (n =36, 22) | 44.861 ± 7.769 | 44.182 ± 7.228 |
| Cycle 19/Day1 (n =29, 14) | 45.379 ± 6.662 | 45.026 ± 7.705 |
| Cycle 20/Day1 (n =20, 12) | 47.050 ± 5.375 | 44.780 ± 6.689 |
| Cycle 21/Day1 (n =15, 7) | 45.850 ± 5.209 | 44.494 ± 6.153 |
| End of treatment (n=163, 191) | 38.328 ± 9.472 | 38.457 ± 8.787 |
| Follow up (n =80, 110) | 41.919 ± 8.318 | 40.028 ± 9.048 |
FKSI-DRS was used to assess quality of life for those diagnosed with renal cell cancer and consisted of 9 items (lack of energy, pain, losing weight, bone pain, fatigue, short of breath, coughing, bothered by fevers, and hematuria). Each of the 9 items was answered on a 5-point Likert-type scale ranging from 0 to 4 (0= not at all, 1= a little bit, 2= somewhat, 3= quite a bit, 4= very much). Total FKSI-DRS score = sum of the 9 item scores; total range: 0 - 36; 0 (no symptoms) to 36 (very much); higher scores indicate greater presence of symptoms.
| Units on a scale | Axitinib 5 mg | Sorafenib 400 mg |
|---|---|---|
| Baseline (n =346, 341) | 28.874 ± 5.187 | 28.975 ± 5.193 |
| Cycle 2/Day1 (n =319, 295) | 28.211 ± 4.920 | 28.399 ± 5.064 |
| Cycle 3/Day1 (n =279, 244) | 28.640 ± 4.837 | 28.640 ± 4.868 |
| Cycle 4/Day1 (n =257, 220) | 28.822 ± 4.952 | 29.130 ± 4.322 |
| Cycle 5/Day1 (n =238, 202) | 28.869 ± 4.880 | 29.007 ± 4.379 |
| Cycle 6/Day1 (n =213, 178) | 29.159 ± 4.462 | 29.098 ± 4.697 |
| Cycle 7/Day1 (n =206, 157) | 29.042 ± 4.581 | 29.361 ± 4.558 |
| Cycle 8/Day1 (n =177, 135) | 29.520 ± 4.346 | 29.619 ± 4.386 |
| Cycle 9/Day1 (n =163, 117) | 29.194 ± 4.937 | 29.884 ± 3.838 |
| Cycle 10/Day1 (n =146, 96) | 29.343 ± 4.907 | 29.604 ± 3.959 |
| Cycle 11/Day1 (n =122, 85) | 29.762 ± 4.943 | 29.366 ± 4.404 |
| Cycle 12/Day1 (n =110, 70) | 29.764 ± 4.507 | 29.257 ± 4.299 |
| Cycle 13/Day1 (n =92, 58) | 29.594 ± 4.205 | 29.666 ± 4.710 |
| Cycle 14/Day1 (n =81, 54) | 29.711 ± 4.313 | 29.820 ± 4.333 |
| Cycle 15/Day1 (n =61, 38) | 30.324 ± 3.582 | 29.500 ± 3.454 |
| Cycle 16/Day1 (n =52, 34) | 30.430 ± 3.443 | 29.474 ± 4.146 |
| Cycle 17/Day1 (n =47, 28) | 30.551 ± 3.331 | 28.737 ± 4.930 |
| Cycle 18/Day1 (n =36, 22) | 30.194 ± 3.992 | 29.045 ± 4.520 |
| Cycle 19/Day1 (n =29, 14) | 30.130 ± 3.636 | 29.286 ± 4.795 |
| Cycle 20/Day1 (n =20, 12) | 31.300 ± 2.736 | 29.250 ± 4.025 |
| Cycle 21/Day1 (n =15, 7) | 31.067 ± 3.173 | 30.143 ± 4.100 |
| End of Treatment (n =163, 191) | 26.288 ± 5.806 | 26.517 ± 5.614 |
| Follow up (n =80, 110) | 28.263 ± 4.802 | 27.516 ± 5.577 |
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility or index score. Health state profile component assesses level of health for 5 domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each domain was rated on a 3-point response scale (1= no problems, 2= some/moderate problems and 3= extreme problems). Scoring formula developed by EuroQol Group assigned a utility value for each domain in the profile. Score were transformed and resulted in a total score range of 0 to 1, with higher scores indicating better health.
| Units on a scale | Axitinib 5 mg | Sorafenib 400 mg |
|---|---|---|
| Baseline (n =347, 341) | 0.732 ± 0.275 | 0.731 ± 0.257 |
| Cycle 2/Day1 (n =326, 307) | 0.716 ± 0.267 | 0.696 ± 0.237 |
| Cycle 3/Day1 (n =287, 248) | 0.722 ± 0.243 | 0.709 ± 0.239 |
| Cycle 4/Day1 (n =262, 226) | 0.730 ± 0.236 | 0.716 ± 0.248 |
| Cycle 5/Day1 (n =244, 207) | 0.730 ± 0.237 | 0.711 ± 0.243 |
| Cycle 6/Day1 (n =221, 178) | 0.734 ± 0.230 | 0.704 ± 0.246 |
| Cycle 7/Day1 (n =213, 163) | 0.718 ± 0.267 | 0.728 ± 0.228 |
| Cycle 8/Day1 (n =181, 136) | 0.756 ± 0.236 | 0.702 ± 0.259 |
| Cycle 9/Day1 (n =169, 120) | 0.760 ± 0.227 | 0.730 ± 0.229 |
| Cycle 10/Day1 (n =151, 98) | 0.734 ± 0.243 | 0.730 ± 0.233 |
| Cycle 11/Day1 (n =126, 87) | 0.764 ± 0.235 | 0.724 ± 0.250 |
| Cycle 12/Day1 (n =110, 73) | 0.744 ± 0.244 | 0.734 ± 0.232 |
| Cycle 13/Day1 (n =96, 61) | 0.760 ± 0.211 | 0.753 ± 0.232 |
| Cycle 14/Day1 (n =80, 57) | 0.723 ± 0.239 | 0.752 ± 0.211 |
| Cycle 15/Day1 (n =63, 41) | 0.730 ± 0.255 | 0.758 ± 0.191 |
| Cycle 16/Day1 (n =54, 37) | 0.749 ± 0.220 | 0.785 ± 0.158 |
| Cycle 17/Day1 (n =48, 29) | 0.779 ± 0.186 | 0.764 ± 0.193 |
| Cycle 18/Day1 (n =37, 20) | 0.755 ± 0.204 | 0.755 ± 0.208 |
| Cycle 19/Day1 (n =29, 14) | 0.734 ± 0.253 | 0.804 ± 0.184 |
| Cycle 20/Day1 (n =21, 12) | 0.794 ± 0.220 | 0.771 ± 0.182 |
| Cycle 21/Day1 (n =16, 7) | 0.700 ± 0.273 | 0.771 ± 0.182 |
| End of Treatment (n =169, 196) | 0.608 ± 0.316 | 0.612 ± 0.310 |
| Follow up (n =76, 106) | 0.682 ± 0.294 | 0.666 ± 0.295 |
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. VAS component: participants rated their current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health.
| Units on a scale | Axitinib 5 mg | Sorafenib 400 mg |
|---|---|---|
| Baseline (n =341, 339) | 70.560 ± 19.187 | 70.351 ± 17.403 |
| Cycle 2/Day1 (n =317, 302) | 69.003 ± 20.195 | 67.606 ± 18.265 |
| Cycle 3/Day1 (n =280, 250) | 69.843 ± 17.927 | 69.712 ± 18.429 |
| Cycle 4/Day1 (n =261, 224) | 69.180 ± 18.636 | 70.759 ± 17.189 |
| Cycle 5/Day1 (n =244, 205) | 69.705 ± 18.330 | 71.888 ± 16.999 |
| Cycle 6/Day1 (n =220, 178) | 69.900 ± 18.168 | 71.365 ± 17.019 |
| Cycle 7/Day1 (n =209, 163) | 69.919 ± 18.063 | 72.282 ± 17.521 |
| Cycle 8/Day1 (n =180, 139) | 70.756 ± 19.183 | 71.475 ± 18.523 |
| Cycle 9/Day1 (n =168, 121) | 70.667 ± 18.556 | 73.380 ± 17.473 |
| Cycle 10/Day1 (n =151, 98) | 70.629 ± 18.680 | 75.102 ± 14.854 |
| Cycle 11/Day1 (n =126, 87) | 72.103 ± 18.064 | 74.586 ± 15.161 |
| Cycle 12/Day1 (n =111, 73) | 71.730 ± 17.276 | 73.959 ± 15.852 |
| Cycle 13/Day1 (n =94, 61) | 70.723 ± 19.147 | 75.693 ± 14.571 |
| Cycle 14/Day1 (n =81, 58) | 69.420 ± 20.286 | 75.362 ± 15.875 |
| Cycle 15/Day1 (n =62, 42) | 73.016 ± 15.325 | 75.357 ± 15.368 |
| Cycle 16/Day1 (n =52, 37) | 70.269 ± 19.272 | 73.676 ± 15.699 |
| Cycle 17/Day1 (n =48, 30) | 71.375 ± 17.840 | 73.767 ± 16.298 |
| Cycle 18/Day1 (n =37, 23) | 70.459 ± 18.853 | 73.870 ± 16.904 |
| Cycle 19/Day1 (n =29, 14) | 71.034 ± 16.963 | 70.571 ± 17.956 |
| Cycle 20/Day1 (n =21, 12) | 73.143 ± 15.347 | 66.917 ± 17.758 |
| Cycle 21/Day1 (n =16, 7) | 74.563 ± 16.054 | 64.714 ± 16.183 |
| End of Treatment (n =166, 197) | 61.759 ± 21.668 | 61.690 ± 20.973 |
| Follow up (n =76, 109) | 64.382 ± 21.392 | 66.037 ± 19.754 |
Collected over From initiation of treatment up to follow-up period (up to 3 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Axitinib 5 mg | — | 146/359 (40.7%) | 337/359 (93.9%) |
| Sorafenib 400 mg | — | 127/355 (35.8%) | 346/355 (97.5%) |
| Event | Axitinib 5 mg | Sorafenib 400 mg |
|---|---|---|
| Disease progressionGeneral disorders | 32/359 | 18/355 |
| DehydrationMetabolism and nutrition disorders | 10/359 | 1/355 |
| AnaemiaBlood and lymphatic system disorders | 0/359 | 8/355 |
| DiarrhoeaGastrointestinal disorders | 8/359 | 5/355 |
| PyrexiaGeneral disorders | 7/359 | 5/355 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 7/359 | 3/355 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 7/359 | 1/355 |
| DeathGeneral disorders | 3/359 | 6/355 |
| Myocardial infarctionCardiac disorders | 6/359 | 4/355 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/359 | 5/355 |
| Event | Axitinib 5 mg | Sorafenib 400 mg |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 208/359 | 195/355 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 100/359 | 183/355 |
| HypertensionVascular disorders | 156/359 | 107/355 |
| FatigueGeneral disorders | 151/359 | 122/355 |
| Decreased appetiteMetabolism and nutrition disorders | 140/359 | 112/355 |
| NauseaGastrointestinal disorders | 128/359 | 84/355 |
| AlopeciaSkin and subcutaneous tissue disorders | 18/359 | 122/355 |
| DysphoniaRespiratory, thoracic and mediastinal disorders | 116/359 | 49/355 |
| Weight decreasedInvestigations | 111/359 | 83/355 |
| RashSkin and subcutaneous tissue disorders | 53/359 | 109/355 |
Full analysis set (FAS) included all participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether participants received study drug or receive a different drug from that to which they were randomized.
| Age, Customized(Participants) | Axitinib 5 mg | Sorafenib 400 mg | Total |
|---|---|---|---|
| Less than (<) 65 years | 238 | 238 | 476 |
| Greater than or equal to (>=) 65 years | 123 | 124 | 247 |
| Sex: Female, Male(Participants) | Axitinib 5 mg | Sorafenib 400 mg | Total |
|---|---|---|---|
| Female | 96 | 104 | 200 |
| Male | 265 | 258 | 523 |
Showing the first 100 of 294 sites across 22 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Sep 2008 to primary completion in Aug 2010, 23 months.
Results were first posted in Mar 2012, 1 year 6 months after primary completion. A results delay was requested in Oct 2010.
Of 22 phase 3 interventional studies under Kidney Neoplasms, half reached primary completion within 70 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 89. This study's 23 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Axitinib